首页> 外文期刊>Trials >Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal replacement therapy for acute renal failure (VERROU-REA study): study protocol for a randomized controlled trial
【24h】

Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal replacement therapy for acute renal failure (VERROU-REA study): study protocol for a randomized controlled trial

机译:需要急性期肾衰竭的肾脏替代治疗的患者中,将非肝性中央静脉血液透析导管的肝素与柠檬酸盐作为导管锁定溶液的比较(VERROU-REA研究):一项随机对照试验的研究方案

获取原文
       

摘要

Background The incidence of acute kidney injury (AKI) is estimated at 10 to 20% in patients admitted to intensive care units (ICU) and often requires renal replacement therapy (RRT). ICU mortality in AKI patients can exceed 50%. Venous catheters are the preferred vascular access method for AKI patients requiring RRT, but carry a risk of catheter thrombosis or infection. Catheter lock solutions are commonly used to prevent such complications. Heparin and citrate locks are both widely used for tunneled, long-term catheters, but few studies have compared citrate versus heparin for patients with short-term, non-tunneled catheters. We aim to compare citrate 4% catheter lock solution versus heparin in terms of event-free survival of the first non-tunneled hemodialysis catheter inserted in ICU patients with AKI requiring RRT. Secondary objectives are the rate of fibrinolysis, incidence of catheter thrombosis and catheter-related infection per 1,000 catheter days, length of stay in ICU and in-hospital and 28-day mortality. Methods/Design The VERROU-REA study is a randomized, prospective, multicenter, double-blind, parallel-group, controlled superiority study carried out in the medical, surgical and nephrological ICUs of two large university hospitals in eastern France. A catheter lock solution composed of trisodium citrate at 4% will be compared to unfractionated heparin at a concentration of 5,000 IU/mL. All consecutive adult patients with AKI requiring extracorporeal RRT, and in whom a first non-tunneled catheter is to be inserted by the jugular or femoral approach, will be eligible. Catheters inserted by the subclavian approach, patients with acute liver failure, thrombopenia or contraindication to systemic anticoagulation will be excluded. Patients will be followed up daily in accordance with standard practices for RRT until death or discharge. Discussion Data is scarce regarding the use of non-tunneled catheters in the ICU setting in patients with AKI. This study will provide an evidence base for recommendations regarding the use of anticoagulant catheter locks for the prevention of dysfunction in non-tunneled hemodialysis catheters in patients with AKI in critical or intensive care. Trial registration Registered with Clinicaltrials.gov (registration number: NCT01962116 ) on 27 August 2013.
机译:背景技术重症监护病房(ICU)的患者急性肾损伤(AKI)的发生率估计为10%至20%,并且经常需要进行肾脏替代治疗(RRT)。 AKI患者的ICU死亡率可超过50%。对于需要RRT的AKI患者,静脉导管是首选的血管通路方法,但存在导管血栓或感染的风险。导管锁定解决方案通常用于防止此类并发症。肝素和柠檬酸盐锁都广泛用于隧道式长期导管,但很少有研究比较短期,非隧道式导管患者的柠檬酸盐和肝素。我们的目的是比较在ICU要求RRT的AKI患者中插入的第一个非隧道式血液透析导管的无事件生存期,比较柠檬酸盐4%导管锁定溶液与肝素的生存率。次要目标是纤溶速率,每1000导管天的导管血栓形成和导管相关感染的发生率,在ICU中的住院时间以及住院和28天死亡率。方法/设计VERROU-REA研究是一项随机,前瞻性,多中心,双盲,平行分组,对照优势研究,在法国东部两家大型大学医院的医疗,外科和肾脏病ICU中进行。将浓度为5,000 IU / mL的由4%柠檬酸三钠组成的导管锁定溶液与普通肝素进行比较。所有需要进行体外RRT的连续AKI成人患者均符合条件,并且需要通过颈或股骨入路插入第一个非隧道式导管。通过锁骨下入路插入的导管,急性肝衰竭,血小板减少症或全身抗凝禁忌症的患者将被排除在外。每天将按照RRT的标准做法对患者进行随访,直至死亡或出院。讨论有关AKI患者在ICU中使用非隧道导管的数据很少。这项研究将为有关使用抗凝导管锁防止重症或重症监护AKI患者预防非隧道式血液透析导管功能障碍的建议提供证据依据。试验注册于2013年8月27日在Clinicaltrials.gov上注册(注册号:NCT01962116)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号